University of California San Francisco | About UCSF | UCSF Benioff Children's Hospital San Francisco
Search Site | Find a Doctor

Lawrence Kaplan, M.D.

Director of the Lymphoma Program

Dr. Lawrence D. Kaplan, a hematologist and oncologist, is director of the Lymphoma Program at UCSF Medical Center and the HIV-Malignancies Program at San Francisco General Hospital. He is an international leader in the treatment of lymphoma and HIV-related malgnancies. In his research, Kaplan is particularly interested in developing new treatments for lymphoma and the HIV-related form of the disease.

His professional activities include serving as former chair of the Steering Committee of the AIDS-Malignancies Clinical Trials Consortium, supported by the National Cancer Institute (NCI) and serving as a member of the Cancer and Leukemia Group B, Lymphoma Committee, a national clinical research group sponsored by the NCI. Kaplan joined UCSF in 1985 and is a clinical professor of medicine. He earned a medical degree at UCLA and completed a fellowship in hematology and oncology at UCSF. He is board certified in medical oncology by the American Board of Internal Medicine.

Clinics

Hematology and Blood and Marrow Transplant
400 Parnassus Ave.,
Suite A-502
San Francisco, CA 94143
Existing Patients: (415) 353-2421
New Patients: (415) 353-2051

Hours: Monday to Friday
8 a.m. – 5 p.m

Conditions & Treatments

More about Lawrence Kaplan

Additional Languages

French

Education

UCLA Medical Center 1980

Residencies

Boston City Hospital, Medicine 1983

Fellowships

UCSF Hematology/Oncology Division, Hematology/Oncology 1985

Selected Research and Publications

  1. Keller JW, Andreadis C, Damon LE, Kaplan LD, Martin TG, Wolf JL, Ai WZ, Venstrom JM, Smith CC, Gaensler KM, Hwang J, Olin RL. Hematopoietic cell transplantation comorbidity index (HCT-CI) is predictive of adverse events and overall survival in older allogeneic transplant recipients. J Geriatr Oncol. 2014 Jul; 5(3):238-44.
  2. Rubenstein JL, Cheson BD, Jung SH, Kaplan LD. Reply to m.C. Chamberlain. J Clin Oncol. 2014 Mar 10; 32(8):858-9.
  3. Kaplan LD, Deitcher SR, Silverman JA, Morgan G. Phase II Study of Vincristine Sulfate Liposome Injection (Marqibo) and Rituximab for Patients With Relapsed and Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma in Need of Palliative Therapy. Clin Lymphoma Myeloma Leuk. 2014 Feb; 14(1):37-42.
  4. Barta SK, Xue X, Wang D, Tamari R, Lee JY, Mounier N, Kaplan LD, Ribera JM, Spina M, Tirelli U, Weiss R, Galicier L, Boue F, Wilson WH, Wyen C, Oriol A, Navarro JT, Dunleavy K, Little RF, Ratner L, Garcia O, Morgades M, Remick SC, Noy A, Sparano JA. Treatment factors affecting outcomes in HIV-associated non-Hodgkin lymphomas: a pooled analysis of 1546 patients. Blood. 2013 Nov 7; 122(19):3251-62.
  5. Rubenstein JL, Wong VS, Kadoch C, Gao HX, Barajas R, Chen L, Josephson SA, Scott B, Douglas V, Maiti M, Kaplan LD, Treseler PA, Cha S, Hwang JH, Cinque P, Cyster JG, Lowell C. CXCL13 plus interleukin 10 is highly specific for the diagnosis of CNS lymphoma. Blood. 2013 Jun 6; 121(23):4740-8.
  6. Rubenstein JL, Hsi ED, Johnson JL, Jung SH, Nakashima MO, Grant B, Cheson BD, Kaplan LD. Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202). J Clin Oncol. 2013 Sep 1; 31(25):3061-8.
  7. Kaplan LD. Human herpesvirus-8: Kaposi sarcoma, multicentric Castleman disease, and primary effusion lymphoma. Hematology Am Soc Hematol Educ Program. 2013; 2013:103-8.
  8. Kaplan LD. Management of HIV-associated Hodgkin lymphoma: how far we have come. J Clin Oncol. 2012 Nov 20; 30(33):4056-8.
  9. Kaplan LD. HIV-associated lymphoma. Best Pract Res Clin Haematol. 2012 Mar; 25(1):101-17.
  10. Barta SK, Lee JY, Kaplan LD, Noy A, Sparano JA. Pooled analysis of AIDS malignancy consortium trials evaluating rituximab plus CHOP or infusional EPOCH chemotherapy in HIV-associated non-Hodgkin lymphoma. Cancer. 2012 Aug 15; 118(16):3977-83.
  11. Armstrong EJ, Bhave P, Wong D, Ursell PC, Kaplan L, Yeghiazarians Y, Ai WZ. Left ventricular rupture due to HIV-associated T-cell lymphoma. Tex Heart Inst J. 2010; 37(4):457-60.
  12. Sparano JA, Lee JY, Kaplan LD, Levine AM, Ramos JC, Ambinder RF, Wachsman W, Aboulafia D, Noy A, Henry DH, Von Roenn J, Dezube BJ, Remick SC, Shah MH, Leichman L, Ratner L, Cesarman E, Chadburn A, Mitsuyasu R. Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma. Blood. 2010 Apr 15; 115(15):3008-16.
  13. Chadburn A, Chiu A, Lee JY, Chen X, Hyjek E, Banham AH, Noy A, Kaplan LD, Sparano JA, Bhatia K, Cesarman E. Immunophenotypic analysis of AIDS-related diffuse large B-cell lymphoma and clinical implications in patients from AIDS Malignancies Consortium clinical trials 010 and 034. J Clin Oncol. 2009 Oct 20; 27(30):5039-48.
  14. Lin L, Lee JY, Kaplan LD, Dezube BJ, Noy A, Krown SE, Levine AM, Yu Y, Hayward GS, Ambinder RF. Effects of chemotherapy in AIDS-associated non-Hodgkin's lymphoma on Kaposi's sarcoma herpesvirus DNA in blood. J Clin Oncol. 2009 May 20; 27(15):2496-502.
  15. Brinker BT, Krown SE, Lee JY, Cesarman E, Chadburn A, Kaplan LD, Henry DH, Von Roenn JH. Phase 1/2 trial of BMS-275291 in patients with human immunodeficiency virus-related Kaposi sarcoma: a multicenter trial of the AIDS Malignancy Consortium. Cancer. 2008 Mar 1; 112(5):1083-8.
  16. Spitzer TR, Ambinder RF, Lee JY, Kaplan LD, Wachsman W, Straus DJ, Aboulafia DM, Scadden DT. Dose-reduced busulfan, cyclophosphamide, and autologous stem cell transplantation for human immunodeficiency virus-associated lymphoma: AIDS Malignancy Consortium study 020. Biol Blood Marrow Transplant. 2008 Jan; 14(1):59-66.
  17. Behler CM, Kaplan LD. Advances in the management of HIV-related non-Hodgkin lymphoma. Curr Opin Oncol. 2006 Sep; 18(5):437-43.
  18. Dunleavy K, Wilson WH, Kaplan LD. The case for rituximab in AIDS-related lymphoma. Blood. 2006 Apr 1; 107(7):3014-5.
  19. Navarro WH, Kaplan LD. AIDS-related lymphoproliferative disease. Blood. 2006 Jan 1; 107(1):13-20.
  20. Kaplan LD, Lee JY, Ambinder RF, Sparano JA, Cesarman E, Chadburn A, Levine AM, Scadden DT. Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010. Blood. 2005 Sep 1; 106(5):1538-43.

Publications are derived from MEDLINE/PubMed and provided by UCSF Profiles, a service of the Clinical & Translational Science Institute (CTSI) at UCSF. Researchers can make corrections and additions to their publications by logging on to UCSF Profiles.